Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | CBLB | Q13191 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 3/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20580593 | 0.84 | KDM4E (0.40) | MTORPIK3CAPIK3CBPRKCAPRKCQ | |
| SCHEMBL20580220 | 0.82 | DGAT1 (0.33) | MTORPIK3CAPIK3CBDGAT1CBLB | |
| SCHEMBL20580219 | 0.82 | DGAT1 (0.33) | MTORPIK3CAPIK3CBDGAT1CBLB | |
| SCHEMBL20580164 | 0.74 | KMT2A (0.33) | CBLBIDH1POLBMEN1KMT2A | |
| SCHEMBL20580192 | 0.72 | CXCR3 (0.34) | MTORPIK3CAPIK3CBDGAT1MAPT | |
| SCHEMBL20580190 | 0.72 | CXCR3 (0.34) | MTORPIK3CAPIK3CBDGAT1MAPT | |
| SCHEMBL20580171 | 0.67 | KDM4E (0.47) | PIK3CAPIK3CBDGAT1MAPTPOLB | |
| SCHEMBL20580596 | 0.65 | KDM4E (0.40) | MTORPIK3CAPIK3CBPRKCAPRKCQ | |
| SCHEMBL542468 | 0.63 | RIPK1 (0.39) | MAPTPOLBKMT2A | |
| SCHEMBL1394234 | 0.60 | RIPK1 (0.41) | MAPTTDP1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20180354912-A1 | ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | disclosed |
| WO-2018226801-A1 | ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354912-A1 | ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | AHR, FURIN, CYP3A5 | MTOR 2838/4885PIK3CA 3359/4885PIK3CB 2984/4885 |
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | AHR, FURIN, CYP3A5 | MTOR 2838/4885PIK3CA 3359/4885PIK3CB 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.